Analysis of drug-induced lung injury in patients with anti-EGFR antibody and ICI

Drug-induced lung injury in patients with anti-EGFR antibody and ICI - DILI in patients with anti-EGFR antibody and ICI

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000046895

Enrollment

150

Registered

2022-02-13

Start date

2020-08-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Head and neck cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Head and neck cancers who were treated with anti-EGFR antibody and/or ICI

Exclusion criteria

Exclusion criteria: Patients without CT findings

Design outcomes

Primary

Measure	Time frame
Incidence of DILI	—

Countries

Japan

Contacts

Public ContactMakoto Arai

T.W.Y.C. Chemotherapy

arai.makoto@twmu.ac.jp047-450-6000

Outcome results